D. Osmanov

发表

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

A. Nademanee, P. Stiff, V. Bachanova, 2015, The Lancet.

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, L. D. De Zwart, J. Snoeys, 2018, Leukemia & lymphoma.

Chromosomal characteristics of malignant lymphoma

L. Konstantinova, E. Fleischman, D. Osmanov, 1989, Human Genetics.

Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.

P. Stiff, V. Bachanova, T. Masszi, 2016, Clinical advances in hematology & oncology : H&O.

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

A. Nademanee, P. Stiff, V. Bachanova, 2015 .

The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

P. Stiff, V. Bachanova, T. Masszi, 2014 .

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

F. Bosch, R. Foà, S. Stilgenbauer, 2021, British journal of haematology.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.

B. Coiffier, J. Sancho, C. Buske, 2017, The Lancet. Haematology.

Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

J. Radford, L. Arcaini, M. Trněný, 2014 .

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

G. Salles, S. Schuster, J. Vermeulen, 2016 .

Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

G. Salles, M. Shipp, P. Zinzani, 2017 .

994OEquivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study

A. Zubel, P. Zhu, W. Jurczak, 2017 .

Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.

B. Coiffier, J. Sancho, C. Buske, 2017 .

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

P. Stiff, T. Masszi, J. Walewski, 2014 .

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

B. Coiffier, J. Sancho, C. Buske, 2016 .

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, J. Snoeys, J. Jiao, 2018, Leukemia & lymphoma.